(Q43035368)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

title

Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

author name string

J G McHutchison

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

J A Shad

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

S C Gordon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

T R Morgan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

M H Ling

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

J J Garaud

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

J K Albrecht

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

language of work or name

1 reference

1 November 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

3 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

414-420

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Therapy of hepatitis C: interferon alfa-2a trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Ultracentrifugation and concentration of a large volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Prolonged therapy of chronic hepatitis C with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00312.X

10.1046/J.1365-2893.2001.00312.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703572%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference